# PGE1 as Additive Anticoagulant in ECMO-Therapy

> **NCT02895373** · PHASE2 · TERMINATED · sponsor: **Thomas Staudinger** · enrollment: 50 (actual)

## Conditions studied

- Respiratory Distress Syndrome, Adult
- Extracorporeal Membrane Oxygenation

## Interventions

- **DRUG:** Alprostadil
- **DRUG:** 0.9% sodium chloride solution

## Key facts

- **NCT ID:** NCT02895373
- **Lead sponsor:** Thomas Staudinger
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07
- **Primary completion:** 2021-05
- **Final completion:** 2021-07
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** After completion of pilot study (n=50) no effect on primary outcome and limited feasibility of recruitment and study procedures
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02895373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02895373, "PGE1 as Additive Anticoagulant in ECMO-Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02895373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*